Al Razi profit rises 5% to SAR 606,000 in H1 2023

Al Razi profit rises 5% to SAR 606,000 in H1 2023

31/08/2023 Argaam Exclusive

View other reports

Al Razi Medical Co. reported a 5% increase in H1 2023 net profit to SAR 606,000, from SAR 580,000 in the year-earlier period, driven by better sales.



Financials (M)

Item 6m 2022 6m 2023 Change‬
Revenues 24.07 30.54 26.9 %
Gross Income 7.10 9.15 29.0 %
Operating Income 0.77 1.00 29.6 %
Net Income 0.58 0.61 4.6 %
Average Shares 1.52 1.52 -
EPS (Riyals) 0.38 0.40 4.6 %


Current Half Annual Comparison (M)

Compared With The
Item H1 2022 H1 2023 Change‬
Revenues 24.07 30.54 26.9 %
Gross Income 7.10 9.15 29.0 %
Operating Income 0.77 1.00 29.6 %
Net Income 0.58 0.61 4.6 %
Average Shares 1.52 1.52 -
EPS (Riyals) 0.38 0.40 4.6 %

Total shareholders’ equity, no minority interest, rose to SAR 23.04 million as of June 30, 2023, from SAR 22.93 million a year earlier.

 

Historical Data

Period

Revenue

(SAR mln)

Net Profit

(SAR mln)

EPS

(SAR)

H1 2022

24.07

0.58

0.38

H2 2022

28.32

1.43

0.94

H1 2023

30.54

0.61

0.40

 



Financial results (Million)

Period Revenues Change Gross Income Change Operating Income Change
H1 2014 - - - - - -
H2 2014 - - - - - -
H1 2015 - - - - - -
H2 2015 - - - - - -
H1 2016 - - - - - -
H2 2016 - - - - - -
H1 2017 - - - - - -
H2 2017 - - - - - -
H1 2018 - - - - - -
H2 2018 - - - - - -
H1 2019 - - - - - -
H2 2019 - - - - - -
H1 2020 - - - - - -
H2 2020 - - - - - -
H1 2021 - - - - - -
H2 2021 - - - - - -
H1 2022 24.07 - 7.10 - 0.77 -
H2 2022 28.32 - 9.01 - 1.82 -
H1 2023 30.54 26.9 % 9.15 29.0 % 1.00 29.6 %


Profit Performance (Million)

Period Net Income Change EPS(Riyal) Extraordinary Income/Expense Net Profit Before Unusual Items EPS Before XO Items
H1 2014 - - - - - -
H2 2014 - - - - - -
H1 2015 - - - - - -
H2 2015 - - - - - -
H1 2016 - - - - - -
H2 2016 - - - - - -
H1 2017 - - - - - -
H2 2017 - - - - - -
H1 2018 - - - - - -
H2 2018 - - - - - -
H1 2019 - - - - - -
H2 2019 - - - - - -
H1 2020 - - - - - -
H2 2020 - - - - - -
H1 2021 - - - - - -
H2 2021 - - - - - -
H1 2022 0.58 - 0.38 - 0.58 0.38
H2 2022 1.43 - 0.94 - 1.43 0.94
H1 2023 0.61 4.6 % 0.40 - 0.61 0.40

Profitability

Period Gross Margin OIBDA Margin Net Margin Before Unusual Items
H1 2014 - - -
H2 2014 - - -
H1 2015 - - -
H2 2015 - - -
H1 2016 - - -
H2 2016 - - -
H1 2017 - - -
H2 2017 - - -
H1 2018 - - -
H2 2018 - - -
H1 2019 - - -
H2 2019 - - -
H1 2020 - - -
H2 2020 - - -
H1 2021 - - -
H2 2021 - - -
H1 2022 - - -
H2 2022 30.73 % 10.07 % 3.84 %
H1 2023 30.84 % 10.49 % 3.47 %


Per Share Data (Riyal)

Compared With The
Period Shares Outstanding (M) EPS (Riyal) Adjusted EPS (Riyal) Book Value (BV)
H1 2014 - - - -
H2 2014 - - - -
H1 2015 - - - -
H2 2015 - - - -
H1 2016 - - - -
H2 2016 - - - -
H1 2017 - - - -
H2 2017 - - - -
H1 2018 - - - -
H2 2018 - - - -
H1 2019 - - - -
H2 2019 - - - -
H1 2020 - - - -
H2 2020 - - - -
H1 2021 - - - -
H2 2021 - - - -
H1 2022 1.52 - - 15.01
H2 2022 1.52 1.33 1.33 15.52
H1 2023 1.52 1.34 1.34 15.16

Multiple Ratios (End of Period Price)

Compared With The
Period P/E Adjusted P/E Price/book
H1 2014 - - -
H2 2014 - - -
H1 2015 - - -
H2 2015 - - -
H1 2016 - - -
H2 2016 - - -
H1 2017 - - -
H2 2017 - - -
H1 2018 - - -
H2 2018 - - -
H1 2019 - - -
H2 2019 - - -
H1 2020 - - -
H2 2020 - - -
H1 2021 - - -
H2 2021 - - -
H1 2022 - - -
H2 2022 - - -
H1 2023 27.11 27.11 2.40

Business Segments (Million)

Compared With The
Period Medicines Cosmetics Baby preparations Medical equipment Medical preparations Other
Q2 2022 9.94 5.22 2.75 2.22 1.97 1.98
Q4 2022 12.52 5.80 3.66 1.98 1.94 2.41
Q2 2023 15.61 3.92 6.87 2.14 2.00 -

Current
Market Cap (M Riyal) 80.56
Enterprise Value (EV) (M) 82.57
Shares Outstanding ((M)) 1.52
Book Value (BV) ( Riyal) 14.72
Par Value ( Riyal) 10.00
Adjusted P/E (Last12) More than 100
Price/book 3.60

Share Price

53.00
3.00 6.00 %

Al-Razi Medical Co. (ALRAZI)


Comments {{getCommentCount()}}

Be the first to comment

{{Comments.indexOf(comment)+1}}
{{comment.FollowersCount}}
{{comment.CommenterComments}}
loader Train
Sorry: the validity period has ended to comment on this news
Opinions expressed in the comments section do not reflect the views of Argaam. Abusive comments of any kind will be removed. Political or religious commentary will not be tolerated.